Immune Checkpoint Inhibition
Showing 1 - 25 of >10,000
Anti-cancer Immune Checkpoint Inhibition TowardsBetter
Not yet recruiting
- Cancer
- (no location specified)
Aug 1, 2023
And Immuno-meDIated Adverse Events in Anti-cancer
Not yet recruiting
- Cancer
- (no location specified)
Jun 26, 2023
Fibrolamellar Hepatocellular Carcinoma Trial in Tuebingen (Fusion-VAC-XS15)
Not yet recruiting
- Fibrolamellar Hepatocellular Carcinoma
-
Tuebingen, Baden-Würtemberg, GermanyUniversity Hospital Tuebingen
Jun 29, 2023
ImPACt on Invasive Fungal Infections by Immune Checkpoint
Completed
- Invasive Fungal Infections
- No intervention
-
Köln, GermanyKlinikum der Universität zu Köln
Oct 31, 2022
Oligometastatic Prostate Cancer Trial in New York (Quemliclustat, Etrumadenant, Zimberelimab)
Not yet recruiting
- Oligometastatic Prostate Cancer
- Quemliclustat
- +3 more
-
New York, New YorkColumbia University Irving Medical Center / NewYork-Presbyterian
Jun 14, 2023
Cutaneous Malignant Melanoma Trial in Cleveland (Low Dose Rate Brachytherapy (LDR), Standard-of-Care Immunotherapy)
Recruiting
- Cutaneous Malignant Melanoma
- Low Dose Rate Brachytherapy (LDR)
- Standard-of-Care Immunotherapy
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
Aug 10, 2022
Colorectal Cancer, Colorectal Carcinoma, Colorectal Adenocarcinoma Trial run by the NCI (Durvalumab, Tremelimumab, Pexa-Vec)
Active, not recruiting
- Colorectal Cancer
- +4 more
- Durvalumab
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 24, 2023
Glioblastoma, Gliosarcoma, Malignant Glioma Trial run by the NCI (TMZ, ipilimumab 3mg/kg, Nivolumab)
Recruiting
- Glioblastoma
- +2 more
- TMZ
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 31, 2023
Cutaneous Metastases Trial in New York (Diphencyprone (DPCP))
Not yet recruiting
- Cutaneous Metastases
- Diphencyprone (DPCP)
-
New York, New YorkIcahn School of Medicine at Mount Sinai
Jul 28, 2022
Liver Metastases, NSCLC Trial in Ann Arbor (Liver SBRT, Pembrolizumab)
Recruiting
- Liver Metastases
- Non-small Cell Lung Cancer
- Liver SBRT
- Pembrolizumab
-
Ann Arbor, MichiganVeterans Affairs Ann Arbor Healthcare System
Jul 27, 2022
Brain Metastases, Non Small Cell Lung Cancer Trial in Durham (Stereotactic Radiosurgery, Immunotherapy)
Recruiting
- Brain Metastases
- Non Small Cell Lung Cancer
- Stereotactic Radiosurgery
- Immunotherapy
-
Durham, North CarolinaDuke Cancer Center
Jun 6, 2022
NSCLC, NSCLC Stage IV Trial in Madison (Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy)
Active, not recruiting
- Non-small Cell Lung Cancer
- Non-small Cell Lung Cancer Stage IV
- Durvalumab
- +2 more
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Sep 21, 2022
NSCLC Stage IV, Melanoma Stage IV, Unresectable Melanoma Trial in Montréal (Camu Camu Capsules (Camu Camu powder encapsulated
Recruiting
- NSCLC Stage IV
- +3 more
- Camu Camu Capsules (Camu Camu powder encapsulated (500mg each) + ICI
-
Montréal, Quebec, CanadaCentre hospitalier de l'Université de Montréal (CHUM)
Jul 18, 2022
Metastatic Pancreatic Cancer, Metastatic Biliary Tract Cancer Trial in Herlev (Nivolumab, Ipilimumab, Radiotherapy)
Active, not recruiting
- Metastatic Pancreatic Cancer
- Metastatic Biliary Tract Cancer
- Nivolumab
- +2 more
-
Herlev, DenmarkHerlev & Gentofte Hospital
Mar 29, 2022
Pancreas Cancer Trial (Nivolumab, Irreversible electroporation (IRE))
Not yet recruiting
- Pancreas Cancer
- Nivolumab
- Irreversible electroporation (IRE)
- (no location specified)
Jun 27, 2022
Breast Cancer Trial in Los Angeles (Pembrolizumab, Olaparib)
Active, not recruiting
- Breast Cancer
-
Los Angeles, CaliforniaCedars-Sinai Medical Center
Feb 1, 2023
Renal Cell Carcinoma, Melanoma Trial (Nivolumab, Pembrolizumab)
Not yet recruiting
- Renal Cell Carcinoma
- Melanoma
- (no location specified)
Oct 7, 2021
Biliary Tract Tumors, Liver Cancer, Hepatocellular Carcinoma Trial run by the NCI (Durvalumab, Tremelimumab, Trans-arterial
Active, not recruiting
- Biliary Tract Neoplasms
- +4 more
- Durvalumab
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Mar 1, 2022
Solid Tumor, Adult Trial in Miami (Pembrolizumab 200 mg Q3W)
Active, not recruiting
- Solid Tumor, Adult
- Pembrolizumab 200 mg Q3W
-
Miami, FloridaMiami Cancer Institute at Baptist Health, Inc.
Nov 18, 2022
Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck
Recruiting
- Advanced Head and Neck Squamous Cell Carcinoma
- +5 more
- Pembrolizumab (immunotherapy)
- Quad-shot palliative radiotherapy
-
Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
Feb 7, 2022
Esophageal Adenocarcinoma Trial in Cologne, München (Durvalumab 50 MG/ML, Tremelimumab)
Recruiting
- Esophageal Adenocarcinoma
- Durvalumab 50 MG/ML
- Tremelimumab
-
Cologne, Germany
- +1 more
Feb 17, 2022
Metastatic Cancer by Radiotherapy Together With Immune
Active, not recruiting
- Metastatic Cancer
- Nivolumab
- +3 more
-
Erlangen, Bavaria, GermanyDepartment of Radiation Oncology, Universitätsklinikum Erlangen
Apr 26, 2021
